Oligofructose-Enriched Inulin
Precancerous Condition
National Cancer Institute (NCI)Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Precancerous Condition cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Darbepoetin Alfa Mayo Clinic | Phase 3 | BB |
Epoetin Alfa Mayo Clinic | Phase 3 | BB |
Cyclophosphamide Institut Paoli-Calmettes | Phase 2 | BB |
CYCLOSPORIN A Institut Paoli-Calmettes | Phase 2 | BB |
Selenium SWOG Cancer Research Network | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Oligofructose-Enriched Inulin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →